PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AlzeCure’s Alzheimer’s candidate shows promise

The treatment abstract focuses on results from a multiple ascending dose study in healthy volunteers.

AlzeCure Pharma – a company that develops a portfolio of small molecule candidate drugs for diseases affecting the central nervous system – has announced an abstract regarding its drug candidate NeuroRestore ACD856.

The therapy, which is being developed with a focus on Alzheimer’s disease, has been accepted for a poster presentation at Alzheimer’s Association International Conference (AAIC) 2022, which will be held in San Diego from 31 July to 4 August.

The abstract, which focuses on results from a multiple ascending dose study in healthy volunteers of ACD856, will be presented at the international Alzheimer’s conference by the project leader, Kristin Önnestam.

The presentation will include new data from the clinical study, the main purpose of which was to evaluate the safety, tolerability and pharmacokinetics of repeated and increasing doses of the treatment.

ACD856 or placebo was given orally repeatedly for one week to 24 healthy subjects divided into three groups in incremental doses. ACD856 has in preclinical studies been shown to improve cognition and memory and is developed primarily for the treatment of Alzheimer’s disease.

“This is a recognition of ACD856, which is the leading drug candidate in the NeuroRestore platform, and its focus on Alzheimer’s disease where there is a great medical need,” explained Kristin Önnestam.

“This new data is very important and we are pleased with this opportunity to present our data at such a well-known international and in an area of increased interest and societal need such as Alzheimer’s and cognitive disorders,” concluded Martin Jönsson, chief executive officer of AlzeCure.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026